Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Figlin on Toxicity Profile of Immunotherapy/VEGF TKI Combinations in RCC

May 9th 2019

Robert A. Figlin, MD, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology/Oncology, deputy director, Integrated Oncology Service Line, and professor of Biomedical Sciences, Medicine, at Cedars-Sinai Medical Center, discusses the toxicity profiles of combinations of immune checkpoint inhibitors and VEGF TKIs in renal cell carcinoma (RCC), as well as research being done to validate potential biomarkers in the space.

Dr. Sznol on Patient Selection for Combination Therapy in mRCC

May 9th 2019

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses patient selection for combination therapy in metastatic renal cell carcinoma.

Dr. Jonasch on Molecular Understanding of Clear Cell RCC

May 8th 2019

Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the molecular understanding of clear cell renal cell carcinoma (RCC).

Dr. McGregor on Implications of the FDA Approval of Pembrolizumab/Axitinib in RCC

May 4th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the clinical implications of the FDA approval of pembrolizumab (Keytruda) and axitinib (Inlyta) in advanced renal cell carcinoma (RCC).

Dr. Grivas on Investigational Immunotherapy Approaches in Localized Bladder Cancer

May 4th 2019

Petros Grivas, MD, PhD, clinical director of the Genitourinary Cancers Program and associate professor, Department of Medicine, Division of Oncology, University of Washington, and medical oncologist, Seattle Cancer Care Alliance, discusses investigational immunotherapy approaches in localized bladder cancer.

Frontline Cabozantinib Plus Nivolumab/Ipilimumab Explored in Phase III RCC Trial

May 2nd 2019

In an effort to improve outcomes for intermediate- or poor-risk patients with renal cell carcinoma, the phase III COSMIC-313 trial is being initiated, which will evaluate cabozantinib (Cabometyx) in combination with nivolumab and ipilimumab in patients with previously untreated advanced disease.

Persistent BCG Shortages Lead to Hard Choices in Bladder Cancer

April 27th 2019

The Tice strain of BCG has emerged as a go-to drug for treating primary and recurrent bladder cancer, but in the United States and some other countries, a constellation of marketplace dynamics has reduced manufacturers of this agent to a sole producer that is unable to keep up with demand. Available supplies are being rationed, and sufficient expansion of supply could be years away.

Dr. Jonasch on Single-Agent Pembrolizumab in Non-Clear Cell RCC

April 24th 2019

Eric Jonasch, MD, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses the use of single-agent pembrolizumab in the treatment of patients with metastatic non–clear cell renal cell carcinoma.

Dr. Sonpavde on the Role of Durvalumab in Platinum-Refractory Bladder Cancer

April 24th 2019

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the role of durvalumab in the treatment of patients with platinum-refractory bladder cancer.

Dr. Rini Discusses Pembrolizumab Plus Axitinib in mRCC

April 24th 2019

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the combination of pembrolizumab plus axitinib in the treatment of patients with metastatic renal cell carcinoma.

Comprehensive Urology Care Does Not Mean Sacrificing Community Connection

April 24th 2019

Implementation of an integrated practice model, in which in-house and outside referrals are available, has enabled Garden State Urology to continue to provide patients with high standards of care while maintaining the familiarity of a community style clinic.

Dr. Figlin on Promise of Immunotherapy Plus TKI Combinations in RCC

April 22nd 2019

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses the promise of immunotherapy plus TKI combinations in the treatment of patients with renal cell carcinoma.

Dr. Powles on FDA Approval of Pembrolizumab Plus Axitinib in Advanced RCC

April 22nd 2019

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the FDA approval of the combination of pembrolizumab (Keytruda) plus axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma (RCC).

FDA Approves Pembrolizumab/Axitinib Combo for Frontline RCC

April 22nd 2019

The FDA has approved pembrolizumab in combination with axitinib for the frontline treatment of patients with advanced renal cell carcinoma.

Dr. Quinn on Current State of Biomarkers in RCC

April 19th 2019

David I. Quinn, MD, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Keck School of Medicine, discusses the current state of biomarkers in renal cell carcinoma.

Biomarkers Needed to Refine Use of Novel Combos in mRCC

April 17th 2019

Neeraj Agarwal, MD, discusses the recent encouraging data reported in mRCC and highlighted the next steps needed to move the needle forward in this space.

Dr. Balar on Improved Outlook in Metastatic Bladder Cancer

April 16th 2019

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone's Perlmutter Cancer Center, discusses the improved outlook for patients with metastatic bladder cancer.

Dr. Figlin on Next Steps for Research in mRCC

April 16th 2019

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses next steps for research in the treatment of patients with metastatic renal cell carcinoma.

Figlin Highlights Immunotherapy Developments in RCC

April 15th 2019

Robert A. Figlin, MD, highlights advances made with immunotherapy in renal cell carcinoma and sheds light on the challenges that remain.

Dr. Grigg on Sequencing in Renal Cell Carcinoma

April 13th 2019

Claud M. Grigg Jr, MD, medical oncologist, Levine Cancer Institute-Ballantyne, Atrium Health, discusses sequencing challenges in renal cell carcinoma (RCC).